100mg

Tarceva

Tarceva 100mg Tablets

Erlotinib

Roche Pakistan Limited.

Drug Identity

Active Ingredient
Erlotinib
Drug Class
Antineoplastics
Chemical Class
Quinazolinamine
Pharmacological Group
on the basis of mechanism of action
ATC Code
L01EB02
Status
Essential Medicine

What is Tarceva?

Uses
Erlotinib is a type of targeted therapy used to treat cancer. Erlotinib is a tyrosine kinase inhibitor that works by blocking the kinase ...

How It Works

Chemical Class
Quinazolinamine
Pharmacological Group
on the basis of mechanism of action

belongs to Quinazolinamine. It belongs to Epidermal Growth Factor Receptor pharmacological group on the basis of mechanism of action. The Molecular Weight of Erlotinib is 429.90. It is strongly acidic drug and Its pKa is 5.42.

How to Take It

1
Adult · oral
100 mg — 24 hourly
For non-small cell PANCREATIC cancer, should be taken at least one hour before or two hours after the ingestion of food.
2
Adult · PO
150 mg — 24 hourly
For non-small cell LUNG cancer, should be taken at least one hour before or two hours after the ingestion of food.
3
Adult
Scraped Dose
Take erlotinib tablets exactly as prescribed by your healthcare provider. Take erlotinib once daily. Take erlotinib on an empty stomach, one hour before food or two hours after food.

Safety Alerts

Do not take erlotinib if you are allergic to erlotinib or any of the ingredients in it
See below for a complete list of ingredients

Important Warnings

Monitor liver function
patients with any hepatic impairment
should be closely monitored, including those with hepatic disease due to tumour burden
Use with caution in patients with or at risk for renal impairment
Monitor closely for dehydration, monitor renal function and electrolytes in patients at risk for dehydration, risk of corneal perforation and ulceration
interrupt or discontinue treatment in patients presenting with eye-pain or other acute or worsening ocular symptoms

Side Effects

Abdominal painanorexiaconjunctivitisdepressiondiarrhoeadry skindyspepsiafatigueflatulenceheadacheneuropathypruritusrigorGI perforationinterstitial lung disease (discontinue). Rare Hepatic failure

Drug Interactions

Conivaptan
proton pump inhibitors (avoid)
vitamin K antagonists
antifungal agents
ciprofloxacin
CY-P3A4 inhibitors or inducers
dasatinib
fluvoxamine

Pregnancy & Lactation

Pregnancy
Positive evidence of risk: Avoid
Lactation
Contraindicated. Discontinue breast-feeding.

Storage

Store Below 30°C.

Price Intelligence

Rs 216,796.09
DRAP approved maximum price · per pack of 30 · approved 07 Aug, 2025
No retail price observed for this pack. Retailers may not exceed the approved maximum.
Prices across sources
DRAPper pack of 30Rs 216,796.09

Should you consider an alternative?

Other options containing Erlotinib, and what they are not.

Identical active ingredient at the same strength. Cheapest per unit first.

Ordered by lowest price per unit where a pack size is known, then by price. Order is never affected by sponsorship. Not medical advice — confirm any change with your pharmacist or doctor.

For pharma professionalsCompany, market and opportunity intelligence

Company

67
brands
79
molecules
3
alerts

Prices as of 30 July 2026 · DRAP ceiling as of 30 July 2026 · schema v3-SKU

For medicine intelligence and professional reference only. Not medical advice.